Compugen To Present Trial-In-Progress Poster On MAIA-Ovarian Phase 1 Study Of COM701, Anti-PVRIG Antibody, At ESMO Gynaecological Cancers Congress 2026

Compugen

Compugen

CGEN

0.00

Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will present a trial-in-progress poster on the MAIA-ovarian Phase 1 study of COM701, a potential first-in-class anti-PVRIG antibody, at the ESMO Gynaecological Cancers Congress 2026, taking place from June 17 to June 19, 2026, in Copenhagen, Denmark.

Poster details:

Title: MAIA-ovarian (NCT06888921) Adaptive Platform Clinical Trial to Evaluate Safety and Efficacy of COM701 Maintenance Treatment in Relapsed Platinum Sensitive Ovarian Cancer (PSOC)

Speaker: Dr. Oladapo Yeku, Massachusetts General Hospital, Boston, MA, U.S.

Poster presentation number: 170

Date and time of poster presentation: June 18, 2026, 12:45 - 13:30 CEST

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.